2.3. Treatment Characteristics
DISEASE
All patients enrolled received a SBRT schedule of 30 Gy in 3 fractions every other day or equivalent regimens (Biologically Effective Dose (BED) > 100 Gy with an α/β  =  1.5 Gy) depending on disease site location. Patients in arm B received 6-months ADT (luteinizing hormone-releasing hormone (LHRH) agonist or antagonist) starting within 1 week before the SBRT treatment.